Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesInnate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response
Journal of Immunology, 09/05/06
Arnon Karni, et al. - Multiple sclerosis (MS) is postulated to be a T cell-mediated autoimmune disease characterized clinically by a relapsing-remitting (RR) stage followed by a secondary progressive (SP) phase. The progressive phase is felt to be secondary to neuronal degenerative changes triggered by inflammation...These results demonstrate abnormalities of DCs in MS and may explain the immunologic basis for the different stages and clinical patterns of MS
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Archives of Neurology, 10/14/09
Changes in Hippocampal Metabolites After Effective Treatment for Fibromyalgia: A Case Study
The Clinical Journal of Pain, 10/20/09
Neurological symptoms in patients with biopsy proven celiac disease
Movement Disorders, 11/03/09
Today in Demyelinating Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The Lancet Neurology, 10/16/09
Sponsor
Article Search
Sponsor